- About Us
-
Our Business
-
- Therapeutic Areas Our portfolio is diverse and based upon - Market Research, Regulatory & IP.
- Licensing Licensing activities are excellent opportunities for companies to expand their portfolio.
- Biosimilar Biosimilar are biologic medicines that are developed to match their reference medicine.
-
- CRAM India has grown to be one of the key nations complying GMP manufacturing norms.
- Medical Devices REVA help our clients to deliver customized, cost-effective medical device value chain.
-
API
-
Dosage form
-
-
Operations
- At Reva, we have requisite infrastructure, with a balanced reach across Regulated, Emerging & Expansion markets. And we are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
-
Research & Development
-
Manufacturing
-
Quality
- Media
- Contact us
INDIA-JAPAN MEDICAL PRODUCTS REGULATION SYMPOSIUM | 18 May, 2016
The 1st INDIA-JAPAN MEDICAL PRODUCTS REGULATION SYMPOSIUM was conducted on 18th & 19th May 2016 at New Delhi. The participation at the symposium was overwhelming with senior government officials from MOHLW (Japan), PMDA (Japan), Ministry of Health, Ministry of Commerce & Industry (INDIA), Drug Regulator (DCGI --INDIA), Pharmexcil, JAPTA, OPMA and Pharma Industry Captains from both nations.
The Ambassador of Japan in India expressed India’s contribution to the generic medicines globally. He emphasised the opening of the generic market of Japan and assured joint working between both countries.
Dr Sandhu (Reva Pharma); as representative of India Pharma Industry; conducted lecture on: “Expectation of India-Japan Partnership & Bilateral co-operationâ€. Dr Sandhu advocated that India needs support from Japan on R&D and offers infrastructure for contract manufacturing (Drug Product & API’s).